Bryan Garnier - VICORE PHARMA (VICOR.ST) VICORE PHARMA | BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: Oct 12, 11 - 12:00 pm EST / 5-6 pm CEST

Report

Bryan Garnier

Eric Yoo

VICORE PHARMA | BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: Oct 12, 11 - 12:00 pm EST / 5-6 pm CEST

This event is intended for institutional clients of Bryan Garnier (BG) only. If you are a client of Bryan Garnier, please register via the link.

05/10/2022 1 EN

Underlying

VICORE PHARMA

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Yoo

Other Reports on these Companies

Bryan Garnier

VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST KOL call details

October 10, 2022 October 10, 2022 1 EN

Bryan Garnier

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4 • -> COVID19 Phase 3 ATTRACT trial is a clearing event • -> We maintain a BUY rating with SEK60 TP, COVID was not in our model

September 16, 2022 September 16, 2022 1 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

10h / 6m 10h / 6m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

10h / 12m 10h / 12m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

10h / 18m 10h / 18m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

VICORE PHARMA | BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: Oct 12, 11 - 12:00 pm EST / 5-6 pm CEST

VICORE PHARMA - BUY | SEK60 Please Join Our Virtual KOL Call to Discuss IPF: 12th October, 11-12 pm EST/5-6 pm CEST

VICORE PHARMA | BUY | SEK60 No biggie, Phase 3 COVID19 data release is a clearing event for IPF update in Q4

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe